Treating Multiple Cancer Types

Market Opportunity

Bringing our innovative therapy to patients across diverse cancer indications

Head & Neck
(HNSCC)

66k+
New US Cases / Year
  • EGFR overexpressed in >90% of cases
  • PI3K/mTOR drives resistance to SOC
  • Strong single-agent rationale

Endometrial
Copy Number Low Subtype

35k+
Annual PI3K Pathway-Driven Cases
  • High PIK3CA mutation frequency (40-50%)
  • PTEN loss creates pathway dependence
  • Combination potential with immunotherapy

Pancreatic
Cancer

64k+
High Unmet Need
  • KRAS mutations in >90% of tumors
  • Exceptional combo data
  • Orphan drug potential

Colorectal
(KRASMT)

153k+
Total CRC Cases (US)
  • Synergy with KRAS inhibitors
  • Addresses rapid adaptive resistance
  • PIK3CA/PTEN alterations in 30-40% of cases

Breast
HER2-Negative MBC

50k+
Annual PIK3CA-Mutant Cases
  • CDK4/6i combination opportunity
  • Reduce adaptive resistance
  • Increase tolerability (reduced hyperglycemia)

Partnership Opportunities

Combination potential with approved & emerging agents

+KRAS G12C/D +CDK4/6 +Radiation

Explore Our Development Pipeline

Learn more about MTX-531 and our brain-penetrant program

View Pipeline